Profil
Corinne Mundin worked as the Director of International Market Development at SyntheMed, Inc. from 2008 to 2011.
She also worked as the Director of International Sales at Novadaq Technologies, Inc. Additionally, she obtained an undergraduate degree from The University of Western Australia.
Ehemalige bekannte Positionen von Corinne Mundin
| Unternehmen | Position | Ende |
|---|---|---|
SyntheMed, Inc.
 SyntheMed, Inc. Medical SpecialtiesHealth Technology SyntheMed, Inc. engages in the development and commercialization of medical devices for therapeutic applications. It focuses on the development and commercialization of anti-adhesion, drug delivery products and other surgical implants. The company's products and product candidates, which are based on its proprietary, bioresorbable polymer technology, are primarily surgical implants designed to prevent or reduce the formation of adhesions following a broad range of surgical procedures. Its commercialization efforts have been focused on its lead product, REPEL-CV Bioresorbable Adhesion Barrier, for use in cardiac surgery. The company has changed its name from Life Medical Sciences, Inc. to SyntheMed, Inc. in May 2005. It was founded in August 1990 and is headquartered in Iselin, NJ | Corporate Officer/Principal | 16.09.2011 |
| NOVADAQ TECHNOLOGIES INC. | Vertrieb & Marketing | - |
Ausbildung von Corinne Mundin
| The University of Western Australia | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
SyntheMed, Inc.
SyntheMed, Inc. Medical SpecialtiesHealth Technology SyntheMed, Inc. engages in the development and commercialization of medical devices for therapeutic applications. It focuses on the development and commercialization of anti-adhesion, drug delivery products and other surgical implants. The company's products and product candidates, which are based on its proprietary, bioresorbable polymer technology, are primarily surgical implants designed to prevent or reduce the formation of adhesions following a broad range of surgical procedures. Its commercialization efforts have been focused on its lead product, REPEL-CV Bioresorbable Adhesion Barrier, for use in cardiac surgery. The company has changed its name from Life Medical Sciences, Inc. to SyntheMed, Inc. in May 2005. It was founded in August 1990 and is headquartered in Iselin, NJ | Health Technology |
Novadaq Technologies, Inc.
 Novadaq Technologies, Inc. Medical SpecialtiesHealth Technology Novadaq Technologies, Inc. was engaged in the development, manufacture, and market of real-time fluorescence imaging products. The company was founded by Rick Mangat on April 14, 2000 and was headquartered in Mississauga, Canada. | Health Technology |
